Copy to clipboard 
Bioventus completed the acquisition of Misonix, a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes. Pursuant to the terms of the merger agreement, Misonix has become a wholly owned subsidiary of Bioventus.
The completed transaction creates a high-growth medical device company that will conduct business as Bioventus Inc. With a $15 billion total addressable market and the ability to gain significant market share across multiple surgical applications as well as wound healing, the combined organization can deliver consistent double-digit revenue growth.
The acquisition is directly aligned with Bioventus’ mission of delivering innovations for active healing to patients and providers. The deal also furthers the company’s strategy of accelerated revenue growth through acquisitions that leverage the company’s existing infrastructure. Together the company will have a significant salesforce focused across surgical applications in spinal fusion, neurosurgery of the cranium and wound treatments including diabetic foot ulcers.
“The commercial reach of the new Bioventus is significantly broader, deeper and even more global. The acquisition has significant revenue growth opportunities via sales call point synergies that we share with Misonix including spinal and lower extremity surgeons. We expect it will accelerate the adoption of the recently launched neXus® platform used to facilitate ultrasonic procedures across spinal decompressions using the BoneScalpel®, SonaStar® for tumor ablation in the cranium and SonicOne® for tissue debridement in chronic wounds. Leading wound products including TheraSkin® will now be available to the entire customer continuum from the office to the wound centers,” said Ken Reali, CEO, Bioventus. “The combination with Misonix allows us to go deeper with our customer base leveraging our infrastructure and benefiting patients, physicians, surgeons as well as our more than 1,200 employees worldwide.”
Source: Bioventus
Bioventus completed the acquisition of Misonix, a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes. Pursuant to the terms of the merger agreement, Misonix has become a wholly owned subsidiary of Bioventus.
The completed transaction creates a high-growth...
Bioventus completed the acquisition of Misonix, a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes. Pursuant to the terms of the merger agreement, Misonix has become a wholly owned subsidiary of Bioventus.
The completed transaction creates a high-growth medical device company that will conduct business as Bioventus Inc. With a $15 billion total addressable market and the ability to gain significant market share across multiple surgical applications as well as wound healing, the combined organization can deliver consistent double-digit revenue growth.
The acquisition is directly aligned with Bioventus’ mission of delivering innovations for active healing to patients and providers. The deal also furthers the company’s strategy of accelerated revenue growth through acquisitions that leverage the company’s existing infrastructure. Together the company will have a significant salesforce focused across surgical applications in spinal fusion, neurosurgery of the cranium and wound treatments including diabetic foot ulcers.
“The commercial reach of the new Bioventus is significantly broader, deeper and even more global. The acquisition has significant revenue growth opportunities via sales call point synergies that we share with Misonix including spinal and lower extremity surgeons. We expect it will accelerate the adoption of the recently launched neXus® platform used to facilitate ultrasonic procedures across spinal decompressions using the BoneScalpel®, SonaStar® for tumor ablation in the cranium and SonicOne® for tissue debridement in chronic wounds. Leading wound products including TheraSkin® will now be available to the entire customer continuum from the office to the wound centers,” said Ken Reali, CEO, Bioventus. “The combination with Misonix allows us to go deeper with our customer base leveraging our infrastructure and benefiting patients, physicians, surgeons as well as our more than 1,200 employees worldwide.”
Source: Bioventus
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
